Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2023 Financial Results
Recursion (RXRX) reported business updates and financial results for Q4 2023 and FY 2023. The company made progress in causal AI modeling, launched LOWE for drug discovery, and provided updates on multiple clinical programs. Recursion's cash position decreased to $391.6 million, with total revenue at $10.9 million for Q4 2023. R&D expenses increased to $69.5 million, and net loss was $93.0 million for Q4 2023.
Positive
Recursion made significant progress in causal AI modeling leveraging over 20 petabytes of precision oncology patient data from Tempus.
The company introduced LOWE, an LLM agent supporting drug discovery programs through natural language prompts.
Updates on clinical programs like Cerebral Cavernous Malformation, Neurofibromatosis Type 2, Familial Adenomatous Polyposis, and more were shared.
Cash and cash equivalents for Recursion decreased to $391.6 million as of December 31, 2023.
Total revenue was $10.9 million for the fourth quarter of 2023, with research and development expenses at $69.5 million.
Net loss for the fourth quarter of 2023 was $93.0 million, reflecting an increase compared to the previous year.
Negative
Revenue decreased in Q4 2023 compared to the previous year due to the timing of workflows from the partnership with Roche-Genentech.
Research and development expenses significantly increased in 2023 compared to 2022, impacting the company's financials.
General and administrative expenses also rose in 2023, primarily driven by increases in salaries, legal expenses, and depreciation.
Net loss widened in Q4 2023 compared to the same period in 2022, indicating financial challenges for the company.
Net cash used in operating activities increased significantly in 2023 compared to the previous year, mainly due to higher operating expenses.
The recent updates from Recursion highlight several key areas that are likely to influence the company's valuation and the broader biotech sector. The progression of multiple clinical programs to Phase 2 readouts in H2 2024 and H1 2025 signals a critical step in the drug development pipeline, potentially affecting the company's future revenue streams and strategic positioning. The in-licensing of a novel fibrotic disease treatment program, 'Target Epsilon', from Bayer and the move into IND-enabling studies could represent a significant market opportunity given the high unmet need in fibrotic diseases.
Moreover, the integration of causal AI models into Recursion's operating system, powered by data from Tempus, emphasizes the company's commitment to leveraging advanced technology to expedite drug discovery. This approach aligns with the industry's ongoing shift towards data-driven R&D, which could lead to more efficient and targeted therapeutic development. The focus on precision oncology and the use of AI to identify potential biomarkers for therapeutics could set a new standard in the industry, potentially impacting the strategies of peer companies and the investment landscape.
Analyzing Recursion's financial health, the reported cash position of $391.6 million as of December 31, 2023, shows a decrease from the previous year, which may raise concerns about the company's burn rate and the need for additional capital in the near future. The reported net loss of $328.1 million for the year ended December 31, 2023, reflects a significant increase from the previous year, which could impact investor sentiment and the company's ability to sustain its R&D efforts without seeking further funding.
However, the increase in revenue from collaboration agreements, primarily with Roche-Genentech, suggests a growing recognition of Recursion's platform and its potential to contribute to the drug discovery process. The strategic collaborations and the potential for option exercises in the near term could offer additional revenue streams and validate the commercial viability of Recursion's technology.
Recursion's strategic focus on leveraging causal AI models and large-scale data analysis to accelerate drug discovery is a testament to the growing trend of integrating computational models in pharmaceutical R&D. The company's LOWE system, which orchestrates complex workflows through natural language prompts, represents a cutting-edge approach to streamlining drug discovery processes. This could potentially reduce the time and costs associated with bringing new drugs to market, offering a competitive advantage and possibly influencing R&D methodologies across the industry.
The emphasis on patient-centric data, such as germline genetic data, in conjunction with organoid technologies and automated nano-synthesis, could lead to more personalized and effective treatments. This approach may also influence regulatory considerations, as agencies like the FDA increasingly prioritize patient-centric data in their evaluation of new therapies.
02/27/2024 - 04:05 PM
Multiple clinical programs from Recursion’s first generation platform are on track to read out Phase 2 data in H2 2024 and H1 2025 with additional second generation programs approaching IND in the near-term In-licensed a program (Target Epsilon) that emerged from our fibrosis collaboration with Bayer that represents a novel approach to treating fibrotic diseases - now entering IND-enabling studies Already incorporating causal AI models into the Recursion OS trained using data from Tempus after a mid-Q4 data partnership announced SALT LAKE CITY, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today reported business updates and financial results for its fourth quarter and fiscal year ending December 31, 2023.
“2023 was a year of remarkable progress for Recursion as we continued to demonstrate how combining technology, biology, chemistry, and patient data can industrialize drug discovery, and we look forward to the milestones ahead of us in 2024,” said Chris Gibson, Ph.D., Co-founder and CEO of Recursion. “As we have watched the dynamics of our landscape, it appears that BioTech is increasingly evolving into TechBio, where it is imperative for life science companies to embrace digital nativity similar to how SaaS companies 10+ years ago evolved to being cloud-native in order to thrive. In this data-driven age, we believe the most important differentiator will be connected data in order to increasingly understand and treat the complexities of human disease. Recursion plans to continue leading the field in terms of data generation and aggregation.”
Summary of Business Highlights
Platform Causal AI Modeling and Additional Datasets: We have been training causal AI models leveraging over 20 petabytes of multimodal precision oncology patient data from Tempus to support the discovery of potential biomarker-enriched therapeutics at scale. By combining the forward genetics approach of Tempus with the reverse genetics approach at Recursion, we believe we have an opportunity to improve the speed, precision, and scale of therapeutic development in oncology. This work has already resulted in a directed-oncology program against a novel gene/disease relationship in a large oncology indication. Recursion intends to operate both as a data generator and multimodal data aggregator. In the future, we intend to augment our dataset and hone the Recursion OS with germline genetic data, organoid technologies, and automated nano-synthesis technologies.LOWE (Large Language Model-Orchestrated Workflow Engine): LOWE is an LLM agent that represents the next evolution of the Recursion OS. LOWE supports drug discovery programs by orchestrating complex wet and dry-lab workflows via natural language prompts. These workflows are the steps and tools available in the Recursion OS, from finding significant relationships across biology, chemistry, and patient-centric data to generating novel compounds and scheduling them for synthesis and experimentation. Through its natural language interface and interactive graphics, LOWE can put state-of-the-art AI tools into the hands of every drug discovery scientist.Pipeline Cerebral Cavernous Malformation (CCM) (REC-994): Our Phase 2 SYCAMORE clinical trial is a randomized, double-blind, placebo-controlled, safety, tolerability and exploratory efficacy study of REC-994 in participants with CCM. This trial was fully enrolled in June 2023 with 62 participants and the vast majority of participants who completed 12 months of treatment continue to elect to enter the long-term extension study. We expect to share Phase 2 data in Q3 2024.Neurofibromatosis Type 2 (NF2) (REC-2282): Our adaptive Phase 2/3 POPLAR clinical trial is a randomized, two part study of REC-2282 in participants with progressive NF2-mutated meningiomas. Part 1 of the study is ongoing and is exploring two doses of REC-2282 in approximately 23 adults and 9 adolescents, with enrollment in adults expected to complete in H1 2024. We expect to share Phase 2 safety and preliminary efficacy data in Q4 2024.Familial Adenomatous Polyposis (FAP) (REC-4881): Our Phase 1b/2 TUPELO clinical trial is an open label, multicenter, two part study of REC-4881 in participants with FAP. Part 1 is complete with FPI for Part 2 anticipated in H1 2024. We expect to share Phase 2 safety and preliminary efficacy data in H1 2025.AXIN1 or APC Mutant Cancers (REC-4881): Our Phase 2 LILAC clinical trial is an open label, multicenter study of REC-4881 in participants with unresectable, locally advanced or metastatic cancer with AXIN1 or APC mutations. This study was initiated at the end of 2023, with FPI anticipated in Q1 2024. We expect to share Phase 2 safety and preliminary efficacy data in H1 2025.Clostridioides difficile Infection (REC-3964): We conducted a Phase 1 healthy volunteer study to evaluate the safety, tolerability, and PK of REC-3964 at increasing oral doses in comparison with placebo. REC-3964 was safe and well tolerated and there were no serious adverse events, deaths, or TEAEs that led to discontinuation. REC-3964 is a first-in-class C. difficile toxin inhibitor and the first new chemical entity developed by Recursion, with promising preclinical efficacy data seen in relevant models (superiority versus bezlotoxumab). We expect to initiate a Phase 2 study in 2024.RBM39 HR-Proficient Ovarian Cancers and Other Solid Tumors: RBM39 is a novel CDK12-adjacent target identified by the Recursion OS. We intend to position our lead candidate as a single agent for the potential treatment of HR-proficient ovarian cancers and other HR-proficient solid tumors. As a result of our strategic collaboration with Tempus, we are leveraging genomic data across all tumor types to identify clinical biomarkers for patient expansion. We are advancing our lead candidate through IND-enabling studies with IND submission expected in H2 2024.Undisclosed Indication in Fibrosis (Target Epsilon): Phenotypic screening of human PBMCs identified novel and structurally diverse small molecules that reverse the phenotypic features of disease-state fibrocyte cells into those of healthy-state cells. The most promising compounds were confirmed as potent inhibitors of a novel target for fibrosis. This program originated under our initial fibrosis collaboration with Bayer and we have since in-licensed from Bayer all rights to this program which is now entering IND-enabling studies.Partnerships Transformational Collaborations: We continue to advance efforts to discover potential new therapeutics with our strategic partners in the areas of undruggable oncology (Bayer) as well as neuroscience and a single indication in gastrointestinal oncology (Roche-Genentech). In the near-term, there is the potential for option exercises associated with partnership programs, option exercises associated with map building initiatives or data sharing, and additional partnerships in large, intractable areas of biology or technological innovation.Enamine: In December 2023, we entered into a collaboration with Enamine to generate and design enriched compound libraries for the global drug discovery industry. By leveraging MatchMaker, a Recursion AI model, to identify compounds in the Enamine REAL Space (~36 billion chemical compounds) predicted to bind to high-value targets, we believe we can generate more powerful compound libraries for drug discovery purposes. Enamine may offer the resulting libraries to customers for purchase and will co-brand any libraries under both the Enamine and Recursion’s trademarks. This collaboration is an example of how select data layers can drive value in novel ways.Additional Corporate Updates
Letter to Shareholders: Recursion Co-Founder & CEO Chris Gibson, Ph.D., wrote an annual letter to shareholders which may be found in the 10-K report.L(earnings) Call: Recursion will host a L(earnings) Call on February 27, 2024 at 5:00 pm Eastern Time / 3:00 pm Mountain Time. A L(earnings) Call is Recursion’s take on interacting with a broad public audience around notable business developments. Recursion will broadcast the live stream from Recursion’s X (formerly Twitter), LinkedIn and YouTube accounts and analysts, investors and the public will be able to ask questions of the company.Chief Business Operations Officer: In February 2024, Recursion named Kristen Rushton, M.B.A. as Chief Business Operations Officer. Ms. Rushton has worked at Recursion for over 6 years, previously serving as Senior Vice President of Business Operations. Prior to Recursion, Ms. Rushton worked at Myriad Genetics and Myrexis.Annual Shareholder Meeting: Recursion’s Annual Shareholder Meeting will be held on June 3, 2024 at 10:00 am Eastern Time / 8:00 am Mountain Time.Fourth Quarter and Fiscal Year 2023 Financial Results
Cash Position: Cash and cash equivalents were $391.6 million as of December 31, 2023, compared to $549.9 million as of December 31, 2022.Revenue: Total revenue, consisting primarily of revenue from collaborative agreements, was $10.9 million for the fourth quarter of 2023, compared to $13.7 million for the fourth quarter of 2022. Total revenue, consisting primarily of revenue from collaboration agreements, was $44.6 million for the year ended December 31, 2023, compared to $39.8 million for the year ended December 31, 2022. For the fourth quarter of 2023, the decrease compared to the prior period was due to the timing of workflows from our strategic partnership with Roche-Genentech. For the year ended December 31, 2023 compared to the prior year, the increase was due to revenue recognized from our Roche-Genentech collaboration, which has progressed from primarily cell type evaluation work to inference based Phenomap building and additional cell type evaluation work.Research and Development Expenses: Research and development expenses were $69.5 million for the fourth quarter of 2023, compared to $44.0 million for the fourth quarter of 2022. Research and development expenses were $241.2 million for the year ended December 31, 2023, compared to $155.7 million for the year ended December 31, 2022. The increase in 2023 research and development expenses compared to the prior year was due to increased platform costs as we have expanded and upgraded our capabilities in platform including our chemical technology, machine learning and transcriptomics platform.General and Administrative Expenses: General and administrative expenses were $30.5 million for the fourth quarter of 2023 compared to $19.8 million for the fourth quarter of 2022. General and administrative expenses were $110.8 million for the year ended December 31, 2023, compared to $81.6 million for the year ended December 31, 2022. The increase in 2023 general and administrative expenses compared to the prior year was primarily driven by an increase in salaries and wages of $12.4 million and increases in legal, software and depreciation expense.Net Loss: Net loss was $93.0 million for the fourth quarter of 2023, compared to a net loss of $57.5 million for the fourth quarter of 2022. Net loss was $328.1 million for the year ended December 31, 2023, compared to a net loss of $239.5 million for the year ended December 31, 2022.Net Cash: Net cash used in operating activities was $74.1 million for the fourth quarter of 2023, compared to net cash used in operating activities of $44.7 million for the fourth quarter of 2022. Net cash used in operating activities was $287.8 million for the year ended December 31, 2023, compared to net cash used in operating activities of $83.5 million for the year ended December 31, 2022. The difference was primarily driven by a $150.0 million upfront payment from Roche-Genentech in early 2022 and an increase in operating expenses in 2023.About Recursion Recursion
Recursion is headquartered in Salt Lake City, where it is a founding member of BioHive www.Recursion.com X LinkedIn
Media Contact Media@Recursion.com
Investor Contact Investor@Recursion.com
Consolidated Statements of Operations
Recursion Pharmaceuticals, Inc. Consolidated Statements of Operations (unaudited) (in thousands, except share and per share amounts) Three months ended Years ended December 31, December 31, 2023 2022 2023 2022 Revenue Operating revenue 10,624 13,676 $ 43,876 $ 39,681 Grant revenue 267 — 699 162 Total revenue 10,891 13,676 44,575 39,843 Operating costs and expenses Cost of revenue 9,881 10,840 42,587 48,275 Research and development 69,482 43,980 241,226 155,696 General and administrative 30,458 19,838 110,822 81,599 Total operating costs and expenses 109,821 74,658 394,635 285,570 Loss from operations (98,930 ) (60,982 ) (350,060 ) (245,727 ) Other income (loss), net 4,306 3,490 17,932 6,251 Loss before income tax benefit (94,624 ) (57,492 ) (332,128 ) (239,476 ) Income tax benefit 1,628 $ — 4,062 $ — Net loss $ (92,996 ) $ (57,492 ) $ (328,066 ) $ (239,476 ) Per share data Net loss per share of Class A, B and Exchangeable $ (0.42 ) $ (0.31 ) $ (1.58 ) $ (1.36 ) Weighted-average shares (Class A, B and 233,158,161 185,669,683 207,853,702 175,537,487
Recursion Pharmaceuticals, Inc. Consolidated Balance Sheets (unaudited) (in thousands) December 31, 2023 2022 Assets Current assets Cash and cash equivalents $ 391,565 $ 549,912 Restricted cash 3,231 1,280 Other receivables 3,094 2,753 Other current assets 40,247 15,869 Total current assets 438,137 569,814 Restricted cash, non-current 6,629 7,920 Property and equipment, net 86,510 88,192 Operating lease right-of-use assets 33,663 33,255 Intangible assets, net 36,443 1,306 Goodwill 52,056 801 Other assets, non-current 261 — Total assets $ 653,699 $ 701,288 Liabilities and stockholders’ equity Current liabilities Accounts payable $ 3,953 $ 4,586 Accrued expenses and other liabilities 46,635 32,904 Unearned revenue 36,426 56,726 Notes payable 41 97 Operating lease liabilities 6,116 5,952 Total current liabilities 93,171 100,265 Unearned revenue, non-current 51,238 70,261 Notes payable, non-current 1,101 536 Operating lease liabilities, non-current 43,414 44,420 Deferred tax liabilities 1,339 — Total liabilities 190,263 215,482 Commitments and contingencies (Note 7) Stockholders’ equity Common stock (Class A, B and Exchangeable) 2 2 Additional paid-in capital 1,431,056 1,125,360 Accumulated deficit (967,622 ) (639,556 ) Total stockholder's equity 463,436 485,806 Total liabilities and stockholders’ equity $ 653,699 $ 701,288
Forward-Looking Statements
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/9dc2dd54-c036-456c-a2d5-867064509f0d
What is the cash position of Recursion as of December 31, 2023?
Recursion's cash and cash equivalents were $391.6 million as of December 31, 2023.
What was the total revenue for the fourth quarter of 2023?
Total revenue for the fourth quarter of 2023 was $10.9 million.
How did research and development expenses change in 2023 compared to 2022?
Research and development expenses increased to $69.5 million in Q4 2023 from $44.0 million in Q4 2022.
What was the net loss for the fourth quarter of 2023?
Net loss was $93.0 million for the fourth quarter of 2023.
Why did net cash used in operating activities increase in 2023 compared to the previous year?
The increase was primarily due to higher operating expenses in 2023.
What caused the decrease in revenue in Q4 2023 compared to the previous year?
The decrease was due to the timing of workflows from the strategic partnership with Roche-Genentech.
What led to the rise in general and administrative expenses in 2023?
The increase was primarily driven by increases in salaries, legal expenses, and depreciation.
How did the company's financial performance in Q4 2023 compare to the same period in 2022?
Net loss widened in Q4 2023 compared to the same period in 2022.
What key updates were provided by Recursion in the PR?
Recursion shared progress in causal AI modeling, introduced LOWE for drug discovery, and provided updates on multiple clinical programs.
Who was appointed as Chief Business Operations Officer in February 2024?
Kristen Rushton, M.B.A. was appointed as Chief Business Operations Officer in February 2024.
